Today: 10 June 2026
Oracle stock slips into after-hours as tech fades on final day of 2025
31 December 2025
2 mins read

Oracle stock slips into after-hours as tech fades on final day of 2025

NEW YORK, December 31, 2025, 4:48 ET — After-hours

  • Oracle shares slipped about 1% in the year’s final session, tracking a softer tape for tech.
  • A recent SEC Form 4 showed an Oracle executive sold 15,000 shares in late December.
  • Investors head into 2026 focused on Oracle’s AI data-center spend and the rate outlook.

Oracle Corp shares were down 1.2% at $194.91 shortly after the close on Wednesday, as trading thinned into the New Year holiday.

The move matters now because Oracle has become a bellwether for investor appetite for big-ticket cloud infrastructure spending tied to artificial intelligence. With the calendar turning, portfolio managers are rebalancing exposure and scrutinizing cash needs across the AI supply chain.

For Oracle, the debate has centered on how quickly cloud demand converts into profit while the company ramps spending on data centers — large, long-lived projects that can weigh on free cash flow before they generate revenue. Interest-rate expectations for 2026 are also key because higher borrowing costs raise the bar for returns on capital-heavy buildouts.

U.S. stocks finished the last session of 2025 lower in light trading, with tech among the weaker areas. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking when liquidity is low. U.S. markets are closed on Thursday for New Year’s Day. Reuters

Oracle traded in step with broader software and mega-cap tech names as investors pared risk into year-end, after a year in which enthusiasm around AI helped lift major indexes to record highs.

Company-specific headlines were limited on Wednesday, but a recent insider-trading disclosure was in focus for some investors. A Form 4 filing showed Oracle executive Mark Hura, president of global field operations, made a gift of 5,000 shares on Dec. 22 and sold 15,000 shares on Dec. 24 at a weighted average price of $196.8876, leaving him with 234,077 shares. A Form 4 is an SEC filing that discloses transactions by company insiders.

Insider sales can be routine, but Oracle’s disclosures are being watched more closely after the company’s December update sharpened the market’s focus on spending. Oracle said earlier this month that capital expenditures for fiscal 2026 would run about $15 billion higher than it had projected in September, alongside a forecast that missed Wall Street expectations.

Investors have also tracked developments around financing for large data-center projects tied to Oracle’s AI push. Oracle said on Dec. 17 that talks for an equity deal to support its Michigan data center project remained on schedule and did not include Blue Owl Capital, after a report on stalled negotiations knocked the shares lower at the time.

Separately, Oracle’s most recent earnings materials reaffirmed shareholder returns through its quarterly dividend. The company’s board declared a $0.50-per-share cash dividend payable on Jan. 23, 2026, to shareholders of record as of Jan. 9, 2026, the company said.

Looking ahead, Oracle says its fiscal third-quarter 2026 earnings will be announced in mid-March 2026.

In the near term, traders will watch whether the stock can stabilize as liquidity returns after the holiday break and as markets recalibrate expectations for Federal Reserve policy in 2026. For Oracle bulls, the key question remains how fast AI-driven cloud demand can translate into sustainable cash generation alongside elevated data-center spending.

With the shares still below the $200 level, investors are also likely to focus on management’s next update on cloud infrastructure capacity additions, customer demand trends and any changes to the company’s capital spending trajectory.

Stock Market Today

  • NULG ETF Sees $250 Million Outflow, 12.4% Dip in Shares Outstanding
    June 10, 2026, 11:47 AM EDT. The NULG exchange-traded fund (ETF) experienced a significant $250 million outflow, marking a 12.4% week-over-week reduction in its shares outstanding from 20.55 million to 18 million units. ETFs trade like stocks but represent ownership in a basket of underlying assets, with unit creation and destruction reflecting investor demand and influencing the fund's asset composition. NULG's latest share price stands at $97.47, near its 52-week high of $99.43, and above its 200-day moving average, a key technical indicator for price trends. Such sizeable outflows can pressure the underlying holdings as the fund liquidates assets to meet redemptions, potentially impacting market dynamics further.

Latest articles

Euro Tech Holdings Shares Slip on High-Volume CLWT Ballast-Water Launch

Euro Tech Holdings Shares Slip on High-Volume CLWT Ballast-Water Launch

10 June 2026
Euro Tech Holdings’ CLWT shares plunged 11.7% to $1.13 on heavy volume after launching a mobile hybrid ballast-water treatment facility, but the company’s announcement lacked customer names, order values, pricing, or a European sales partner, leaving investors with more questions than answers as the stock’s move outpaced any disclosed commercial progress.
Ming Shing Group Holdings shares surge, then fall back after $110M graphene move raises dilution questions

Ming Shing Group Holdings shares surge, then fall back after $110M graphene move raises dilution questions

10 June 2026
Ming Shing Group Holdings shares soared to $5.54 before plunging to $1.74 after closing a $110 million acquisition of PMA Nano Carbon Tech, paid with convertible notes that could create over 111 million new shares at $0.99 each, raising dilution concerns as investors weigh the company’s pivot from construction to graphene technology amid management turnover and a June 16 vote on massively increasing authorized shares.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop